Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
GlobeNewswire
· *The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or..